Clinical Trial Update: Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of trametinib (GSK1120212) and gemcitabine in subjects with solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Solid Tumors

Drugs mentioned

• GSK1120212 (trametinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Leukaemia, Myelocytic, Acute | Phase 1 | Status: COMPLETED